Cardio Diagnostics Holdings (NASDAQ: CDIO) is bringing molecular precision to a critical blind spot in coronary heart disease detection. According to a press release from the company, approximately 50% of individuals with coronary heart disease do not present with traditional risk factors, and conventional risk calculators have an average sensitivity of only 39%. This means that many people who appear healthy may still develop coronary heart disease and experience preventable cardiac events such as heart attacks.
Coronary heart disease remains the leading cause of death in the United States, yet the tools doctors have long relied on for early detection are proving less reliable than many patients assume. For decades, cardiovascular risk assessment has centered on a checklist of factors—cholesterol levels, blood pressure, smoking history, diabetes status, family history, and weight. While these factors are useful, they were never designed to capture the full biological picture of how heart disease develops.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics, fields that examine how genes are expressed and regulated at the molecular level. These tests aim to identify coronary heart disease risk in individuals who might otherwise be missed by traditional methods. The company’s approach could potentially shift the paradigm from a one-size-fits-all risk assessment to a more personalized, molecular-based evaluation.
The implications of this announcement are significant. If molecular precision can improve detection rates, it could reduce the number of preventable cardiac events and deaths. For the healthcare industry, this could mean a move toward integrating epigenetic and genetic testing into standard cardiovascular screening protocols. For individuals, especially those without traditional risk factors, it offers the possibility of earlier intervention and better outcomes.
Forward-looking statements in the release caution that actual results may differ materially from those expressed or implied, due to risks and uncertainties detailed in the company's filings with the SEC. However, the company’s focus on molecular diagnostics underscores a growing recognition that conventional risk calculators have limitations.
For more information on the terms of use and disclaimers, visit IBN.fm/Disclaimer. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
